ArticleAmerican journal of respiratory and critical care medicine2006
IL-12 p80 is an innate epithelial cell effector that mediates chronic allograft dysfunction.
Article in American journal of respiratory and critical care medicine, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- [18F]fluorodeoxyglucose positron emission tomography for lung antiinflammatory response evaluation.American journal of respiratory and critical care medicine · 2009Trial
- IL-12p40 deletion aggravates lipopolysaccharide-induced cardiac dysfunction in mice.Frontiers in cardiovascular medicine · 2022Article
- Association of IL-12 and TNF-α Polymorphisms with Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients.International journal of organ transplantation medicine · 2019Article
- Interferon induced protein 35 exacerbates H5N1 influenza disease through the expression of IL-12p40 homodimer.PLoS pathogens · 2018Article
- IL-12p40 Homodimer Ameliorates Experimental Autoimmune Arthritis.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Suppressor of cytokine signaling 4 (SOCS4) protects against severe cytokine storm and enhances viral clearance during influenza infection.PLoS pathogens · 2014Article
- Interleukin-12p40 modulates human metapneumovirus-induced pulmonary disease in an acute mouse model of infection.PloS one · 2012Article
- Accelerated wound healing phenotype in Interleukin 12/23 deficient mice.Journal of inflammation (London, England) · 2011Article
- Lung transplantation: infection, inflammation, and the microbiome.Seminars in immunopathology · 2011Review
- Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis.Respiratory research · 2010Article
- Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2010Article
- Inhibition of secretion of interleukin (IL)-12/IL-23 family cytokines by 4-trifluoromethyl-celecoxib is coupled to degradation via the endoplasmic reticulum stress protein HERP.The Journal of biological chemistry · 2010Article
- Combination use of immune complexes and a Ca2(+) channel blocker azelnidipine enhances interleukin-12 p40 secretion without T helper type 17 cytokine secretion in human monocyte-derived dendritic cells.Clinical and experimental immunology · 2009Article
- IL-12 p80-dependent macrophage recruitment primes the host for increased survival following a lethal respiratory viral infection.Immunology · 2009Article
- A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy.The Journal of experimental medicine · 2008Article
- Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection.The Journal of experimental medicine · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
rationaleBronchiolitis obliterans syndrome is the leading cause of chronic lung allograft dysfunction. We have demonstrated that respiratory viral infection is a bronchiolitis obliterans syndrome risk factor and virus-dependent injury induces expression of innate airway epithelial genes belonging to the interleukin (IL)-12 family. Thus, we hypothesized that epithelial cell IL-12 family members could mediate lung allograft dysfunction.
objectivesWe used mouse and human allograft specimens to evaluate the role of epithelial cell IL-12 family members in allograft dysfunction associated with and without viral infection.
methodsMurine and human IL-12 family members were characterized and manipulated in allografts and then correlated with epithelial cell injury, immune cell accumulation, and collagen deposition.
resultsIn a mouse model of lung transplantation, concurrent viral infection and allogeneic transplantation increased epithelial injury and this was followed by exaggerated accumulation of macrophages and collagen deposition. This virus-driven allograft dysfunction was associated with an epithelial innate response manifested by a synergistic increase in the production of the macrophage chemoattractant IL-12 p80 (p80), but not IL-12 or IL-23. Blockade or overexpression of donor epithelial p80 resulted in a corresponding abrogation or enhancement of macrophage accumulation and allograft dysfunction. We extended these findings to human recipients with viral infection and transplant bronchitis and again observed excessive epithelial p80 expression that correlated with increased macrophage accumulation.
conclusionsThese experiments support a role for an enhanced epithelial innate response as a central process in allograft dysfunction and identify the macrophage chemoattractant p80 as an innate epithelial effector of disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.